TY - JOUR
T1 - Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24
AU - Zanke, Brent W.
AU - Greenwood, Celia M.T.
AU - Rangrej, Jagadish
AU - Kustra, Rafal
AU - Tenesa, Albert
AU - Farrington, Susan M.
AU - Prendergast, James
AU - Olschwang, Sylviane
AU - Chiang, Theodore
AU - Crowdy, Edgar
AU - Ferretti, Vincent
AU - Laflamme, Philippe
AU - Sundararajan, Saravanan
AU - Roumy, Stéphanie
AU - Olivier, Jean François
AU - Robidoux, Frédérick
AU - Sladek, Robert
AU - Montpetit, Alexandre
AU - Campbell, Peter
AU - Bezieau, Stephane
AU - O'Shea, Anne Marie
AU - Zogopoulos, George
AU - Cotterchio, Michelle
AU - Newcomb, Polly
AU - McLaughlin, John
AU - Younghusband, Ban
AU - Green, Roger
AU - Green, Jane
AU - Porteous, Mary E.M.
AU - Campbell, Harry
AU - Blanche, Helene
AU - Sahbatou, Mourad
AU - Tubacher, Emmanuel
AU - Bonaiti-Pellié, Catherine
AU - Buecher, Bruno
AU - Riboli, Elio
AU - Kury, Sebastien
AU - Chanock, Stephen J.
AU - Potter, John
AU - Thomas, Gilles
AU - Gallinger, Steven
AU - Hudson, Thomas J.
AU - Dunlop, Malcolm G.
N1 - Funding Information:
The authors thank D. Daftary and T. Selander at the Mount Sinai Hospital Biorepository for technical and administrative assistance with OFCCR samples. We also are grateful to A. Bélisle, S. Roland, M.-C. Tessier and D. Vincent of the McGill University and Génome Québec Innovation Centre for technical genotyping assistance. We acknowledge all those involved in recruitment and assembly of the biological and data resources of the Colorectal Cancer Genetic Susceptibility (COGS) study and the Scottish Colorectal Cancer Study (SOCCS), including the Edinburgh Wellcome Trust Clinical Research Facility and also the Family Practitioner Services Department, the Cancer Intelligence Unit of the Information and Statistics Division (ISD) and Scottish Cancer Registry Cancer, all of the Scottish Central National Health Service (NHS). C. Bonithon-Kopp, A. Pariente, B. Nalet and J. Lafon (Group d’Etude des Adenomas) and members of the Association Nationale des Gastroenterologues des Hopitaux Généraux. For administrative assistance, we acknowledge L. Blahut (Cancer Care Ontario). We are grateful to the nursing, laboratory and office staff throughout Edinburgh, at the Wellcome Trust Clinical Research Facility and at the central Scottish NHS departments, including Cancer Registry and the Scottish Cancer Intelligence Unit of ISD. Cancer Care Ontario, as the host organization to the ARCTIC Genome Project, acknowledges that this Project was funded by Genome Canada through the Ontario Genomics Institute, by Génome Québec, the Ministère du Dévelopement Économique et Régional et de la Recherche du Québec and the Ontario Institute for Cancer Research (B.W.Z., T.J.H., C.M.T.G, S.G. and M.C.). This work was supported through collaboration and cooperative agreements with
Funding Information:
the Colon Cancer Family Registry and principal investigators supported by the US National Cancer Institute, US National Institutes of Health under RFA CA-95-011, including S.G. at the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA076783) and J.P. at the Seattle Colorectal Cancer Family Registry (U01 CA074794). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating institutions or investigators in the Colon Familial Registry, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government or the Colon CFR. This work was supported through collaboration and cooperative agreement with the Newfoundland Familial Colon Cancer Registry at the Memorial University of Newfoundland (B.Y., R.G., J.G.). The work in Scotland was supported by Cancer Research UK (C348/A3758, C48/ A6361), the UK Medical Research Council (G0000657-53203) and the Scottish Executive Chief Scientist’s Office (K/OPR/2/2/D333, CSO CZB/4/94) (M.D.) and by a Centre Grant from the Digestive Disorders Foundation ( http:// www.corecharity.org.uk). Support in France came from the French Ministry of Research, Fondation de France (S.O., C.B.P.), Projet Hospitalier de Researche Clinique (PHRC) AOM01-006 (G.T.), Ligue Nationale contre le Cancer (G.T.), Groupement des Enterprises Francaises dans la Lutte contre le Cancer (GEFLUC) (S.B.) and the European Commission (E.R.). Support is acknowledged from the National Program for Complex Data Structures (Canada) (R.K.) and the Centre for Applied Genomics (Toronto) (C.G.).
PY - 2007/8
Y1 - 2007/8
N2 - Using a multistage genetic association approach comprising 7,480 affected individuals and 7,779 controls, we identified markers in chromosomal region 8q24 associated with colorectal cancer. In stage 1, we genotyped 99,632 SNPs in 1,257 affected individuals and 1,336 controls from Ontario. In stages 2-4, we performed serial replication studies using 4,024 affected individuals and 4,042 controls from Seattle, Newfoundland and Scotland. We identified one locus on chromosome 8q24 and another on 9p24 having combined odds ratios (OR) for stages 1-4 of 1.18 (trend; P = 1.41 × 10-8) and 1.14 (trend; P = 1.32 × 10-5), respectively. Additional analyses in 2,199 affected individuals and 2,401 controls from France and Europe supported the association at the 8q24 locus (OR = 1.16, trend; 95% confidence interval (c.i.): 1.07-1.26; P = 5.05 × 10-4). A summary across all seven studies at the 8q24 locus was highly significant (OR = 1.17, c.i.: 1.12-1.23; P = 3.16 × 10-11). This locus has also been implicated in prostate cancer.
AB - Using a multistage genetic association approach comprising 7,480 affected individuals and 7,779 controls, we identified markers in chromosomal region 8q24 associated with colorectal cancer. In stage 1, we genotyped 99,632 SNPs in 1,257 affected individuals and 1,336 controls from Ontario. In stages 2-4, we performed serial replication studies using 4,024 affected individuals and 4,042 controls from Seattle, Newfoundland and Scotland. We identified one locus on chromosome 8q24 and another on 9p24 having combined odds ratios (OR) for stages 1-4 of 1.18 (trend; P = 1.41 × 10-8) and 1.14 (trend; P = 1.32 × 10-5), respectively. Additional analyses in 2,199 affected individuals and 2,401 controls from France and Europe supported the association at the 8q24 locus (OR = 1.16, trend; 95% confidence interval (c.i.): 1.07-1.26; P = 5.05 × 10-4). A summary across all seven studies at the 8q24 locus was highly significant (OR = 1.17, c.i.: 1.12-1.23; P = 3.16 × 10-11). This locus has also been implicated in prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=34547092701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547092701&partnerID=8YFLogxK
U2 - 10.1038/ng2089
DO - 10.1038/ng2089
M3 - Article
C2 - 17618283
AN - SCOPUS:34547092701
SN - 1061-4036
VL - 39
SP - 989
EP - 994
JO - Nature genetics
JF - Nature genetics
IS - 8
ER -